At ACC, Merck indicated it is leaning toward using a lower Winrevair dose for a pivotal Phase 3 trial in an uncommon form of heart failure. The decision follows a Phase 2 signal described as “pretty profound” at the lowest tested dose, prompting the company to recalibrate which dose will move forward into the registrational setting.